Authors
- Priyadarshini R. JadhavDepartment of Dermatology, D. Y. Patil Medical College and Hospital, Kolhapur Maharashtra, India
- Sagar GoyalMBBS Intern, D. Y. Patil Medical College and Hospital, Kolhapur, Maharashtra, India
- SheetalMBBS Student, Jawaharlal Nehru Medical College, Sawangi (Datta Meghe), Wardha, Maharashtra, India
- Gayatri DhavalshankhDepartment of Pharmacology, D. Y. Patil Medical College and Hospital, Kolhapur, Maharashtra, India
- Archana DhavalshankhDepartment of Pharmacology, D. Y. Patil Medical College and Hospital, Kolhapur, Maharashtra, India
- Ganesh DhavalshankhDepartment of Dermatology, D. Y. Patil Medical College and Hospital, Kolhapur Maharashtra, India
DOI:
https://doi.org/10.18203/2394-6040.ijcmph20242885Keywords:
Apremilast, Hepatotoxicity, Liver function tests, Psoriasis, TofacitinibAbstract
Background: Psoriasis is a chronic inflammatory skin disease that requires long-term management, often necessitating systemic treatments for moderate to severe cases. Tofacitinib, a Janus kinase (JAK) inhibitor, and apremilast, a phosphodiesterase 4 (PDE4) inhibitor, are increasingly used in refractory cases. Monitoring liver function is crucial due to potential hepatotoxicity. This study compared the impact of tofacitinib and apremilast on liver function tests (LFTs) over 12 months in patients with refractory psoriasis.
Methods: A retrospective cohort study was conducted at D. Y. Patil Hospital, Kolhapur, involving 150 patients treated between January 2019 and December 2021. Patients received either tofacitinib (5 mg twice daily) or apremilast (30 mg twice daily) for at least 12 months. Exclusion criteria included a history of liver disease, significant alcohol consumption, and incomplete medical records. Baseline and follow-up LFTs at 3, 6, and 12 months were analyzed using paired t-tests and independent t-tests.
Results: Among 150 patients, 75 were treated with tofacitinib and 75 with apremilast. Baseline characteristics, including LFTs, were similar between groups. The tofacitinib group exhibited significant increases in ALT and AST levels at all follow-up points compared to the apremilast group (p<0.01). Mean ALT rose from 25.6 U/l to 42.3 U/l in the tofacitinib group, while in the apremilast group, it increased from 24.9 U/l to 28.9 U/l. ALP and bilirubin levels remained stable.
Conclusions: Tofacitinib is associated with higher incidence of liver enzyme elevations than apremilast. Regular liver function monitoring is recommended for patients on tofacitinib.
References
Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377-85.
Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997):983-94.
Ogdie A, Weiss P. The epidemiology of psoriatic arthritis. Rheum Dis Clin North Am. 2015;41(4):545-68.
Lowes MA, Suárez-Fariñas M, Krueger JG. Immunology of psoriasis. Annu Rev Immunol. 2014;32:227-55.
Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496-509.
Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370(9583):263-71.
Lebwohl M. Psoriasis. Lancet. 2003;361(9364):1197-204.
Papp KA. Long-term safety of biologics for psoriasis: A review of the literature. J Dermatol Treat. 2020;31(1):6-10.
Greb JE, Goldminz AM, Elder JT, Lebwohl MG, Gladman DD, Wu JJ, et al. Psoriasis. Nat Rev Dis Primers. 2016;2:16082.
Papp KA, Menter MA, Strober B, Langley RG, Korman NJ, Zeldis JB, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. Br J Dermatol. 2015;173(4):949-61.
Mease P, Hall S, FitzGerald O, van der Heijde D, Merola JF, Avila-Zapata F, Cieślak D, Graham D, Wang C, Menon S, Hendrikx T, Kanik KS. Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis. N Engl J Med. 2017 Oct 19;377(16):1537-50.
Kremer JM, Bloom BJ, Breedveld FC, Coombs JH, Fletcher MP, Gruben D, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum. 2009;60(7):1895-905.
Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012;83(12):1583-90.
LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases; 2012.
Papp KA. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study. J Eur Acad Dermatol Venereol. 2013;27(3):e376-83.
Álvaro-Gracia JM. Update on the Safety Profile of Tofacitinib in Rheumatoid Arthritis from Clinical Trials to Real-World Studies: A Narrative Review. Rheumatol Ther. 2021;8(1):17-40.
Crowley J. Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). J Am Acad Dermatol. 2017;77(2):310-317.e1.
Sandborn WJ. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376(18):1723-36.
U.S. Food and Drug Administration. Xeljanz (tofacitinib) Prescribing Information. Available from: https://www.accessdata.fda. gov/drugsatfda _docs/label/2019/203214s021lbl.pdf). Accessed on 15 September 2019.
